Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OXiGENE, a clinical-stage biopharmaceutical company, has appointed John Kollins, the company's current COO, to the positions of CEO and director. Concurrently, the company's board accepted the resignation of Richard Chin as president and CEO and as a member of the board of directors.
Subscribe to our email newsletter
Joel Citron, chairman of the OXiGENE board of directors, said: “The board has complete confidence in John’s ability to lead OXiGENE through its next stages of development, to provide clear strategic direction in implementing the company’s clinical, operational and business strategies, and to effectively represent OXiGENE in its relationships with key stakeholders.
“Since joining the company in March 2007, John has consistently provided strategic guidance and maintained a strong focus on high-quality execution in all aspects of OXiGENE’s business. With his wealth of industry experience, John is our best choice to ensure that OXiGENE realizes its full potential, successfully delivers on its goals and builds shareholder value.”